Cost of epilepsy in the Russian Federation

Background. Epilepsy underdiagnosis in Russia, population aging, innovative drugs and expensive treatment regimens, the introduction of additional and alternative methods such as neurosurgery, annually increase the cost for treatment of epilepsy patients. In this regard, an issue of maximizing benef...

Full description

Saved in:
Bibliographic Details
Main Authors: A. S. Romanov, E. F. Sharakhova, N. I. Shova, V. A. Mikhailov
Format: Article
Language:Russian
Published: IRBIS LLC 2024-10-01
Series:Эпилепсия и пароксизмальные состояния
Subjects:
Online Access:https://www.epilepsia.su/jour/article/view/1102
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849249494441394176
author A. S. Romanov
E. F. Sharakhova
N. I. Shova
V. A. Mikhailov
author_facet A. S. Romanov
E. F. Sharakhova
N. I. Shova
V. A. Mikhailov
author_sort A. S. Romanov
collection DOAJ
description Background. Epilepsy underdiagnosis in Russia, population aging, innovative drugs and expensive treatment regimens, the introduction of additional and alternative methods such as neurosurgery, annually increase the cost for treatment of epilepsy patients. In this regard, an issue of maximizing benefits for the largest number of the population becomes relevant. Pharmacoeconomical research within the assessment of healthcare technologies helps to choose the most economically and medically effective treatment strategy among numerous alternatives.Objective: analysis of epilepsy-associated costs in the Russian Federation, aimed at supporting decision-making processes in the field of health policy and financing.Material and methods. The empirical study was based on collecting the data on a continuous sampling of 384 epilepsy outpatient records from subjects aged 19 to 79 years for the period 2019–2022. The issues related to all costs of epilepsy were discussed. While planning, conducting and analyzing these studies, the principles of strengthening the reporting of observational studies in epidemiology (STROBE) were taken into account.Results. The total annual per-patient expenditure on epilepsy treatment comprised a fifth of gross domestic product per capita. Indirect costs exceed direct cost savings. It was found out that the economic damage caused to society, family, and individual related to epilepsy is three times higher than the direct costs.Conclusion. The results obtained are consistent with other publications in which unemployment among epilepsy patients is one of the major cost-determining factors and illustrates a critical need to maintain employment for such patients or to find suitable alternative work through professional retraining.
format Article
id doaj-art-d16c35051877487091d8188dcc1224ae
institution Kabale University
issn 2077-8333
2311-4088
language Russian
publishDate 2024-10-01
publisher IRBIS LLC
record_format Article
series Эпилепсия и пароксизмальные состояния
spelling doaj-art-d16c35051877487091d8188dcc1224ae2025-08-20T03:57:32ZrusIRBIS LLCЭпилепсия и пароксизмальные состояния2077-83332311-40882024-10-0116310.17749/2077-8333/epi.par.con.2024.186650Cost of epilepsy in the Russian FederationA. S. Romanov0E. F. Sharakhova1N. I. Shova2V. A. Mikhailov3Altai State Medical UniversityAltai State Medical UniversityBekhterev National Medical Research Center for Psychiatry and NeurologyBekhterev National Medical Research Center for Psychiatry and Neurology; Almazov National Medical Research CentreBackground. Epilepsy underdiagnosis in Russia, population aging, innovative drugs and expensive treatment regimens, the introduction of additional and alternative methods such as neurosurgery, annually increase the cost for treatment of epilepsy patients. In this regard, an issue of maximizing benefits for the largest number of the population becomes relevant. Pharmacoeconomical research within the assessment of healthcare technologies helps to choose the most economically and medically effective treatment strategy among numerous alternatives.Objective: analysis of epilepsy-associated costs in the Russian Federation, aimed at supporting decision-making processes in the field of health policy and financing.Material and methods. The empirical study was based on collecting the data on a continuous sampling of 384 epilepsy outpatient records from subjects aged 19 to 79 years for the period 2019–2022. The issues related to all costs of epilepsy were discussed. While planning, conducting and analyzing these studies, the principles of strengthening the reporting of observational studies in epidemiology (STROBE) were taken into account.Results. The total annual per-patient expenditure on epilepsy treatment comprised a fifth of gross domestic product per capita. Indirect costs exceed direct cost savings. It was found out that the economic damage caused to society, family, and individual related to epilepsy is three times higher than the direct costs.Conclusion. The results obtained are consistent with other publications in which unemployment among epilepsy patients is one of the major cost-determining factors and illustrates a critical need to maintain employment for such patients or to find suitable alternative work through professional retraining.https://www.epilepsia.su/jour/article/view/1102epilepsydirect costsindirect costscost-of-illness analysishealth technology assessment
spellingShingle A. S. Romanov
E. F. Sharakhova
N. I. Shova
V. A. Mikhailov
Cost of epilepsy in the Russian Federation
Эпилепсия и пароксизмальные состояния
epilepsy
direct costs
indirect costs
cost-of-illness analysis
health technology assessment
title Cost of epilepsy in the Russian Federation
title_full Cost of epilepsy in the Russian Federation
title_fullStr Cost of epilepsy in the Russian Federation
title_full_unstemmed Cost of epilepsy in the Russian Federation
title_short Cost of epilepsy in the Russian Federation
title_sort cost of epilepsy in the russian federation
topic epilepsy
direct costs
indirect costs
cost-of-illness analysis
health technology assessment
url https://www.epilepsia.su/jour/article/view/1102
work_keys_str_mv AT asromanov costofepilepsyintherussianfederation
AT efsharakhova costofepilepsyintherussianfederation
AT nishova costofepilepsyintherussianfederation
AT vamikhailov costofepilepsyintherussianfederation